FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to clinical immunology, and can be used for assessment of actual vaccination of people against brucellosis. For this purpose, in antigen-specific tests in vitro using flow cytometry on 14th day after vaccination, the number of lymphocytes expressing CD25 receptors upon stimulation with a brucellous antigen is determined, twofold increase of the number of the latter indicates formation of specific cellular immunity in the vaccinated.
EFFECT: use of the given invention enables by results of accounting for the amount of antigen-activated CD3+CD25+ lymphocytes assessing the immunological effectiveness of vaccine on 14th day after immunization, regardless of the presence and level of specific seroconversion.
1 cl, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR ASSESSING PROTECTIVE IMMUNITY AGAINST CAUSATIVE AGENT OF BRUCELLOSIS | 2022 |
|
RU2806161C1 |
| METHOD OF OBTAINING A BRUCELLAROTIC ANTIGEN FOR CELL TESTS IN VITRO | 2019 |
|
RU2708561C1 |
| METHOD FOR IMMUNOLOGICAL DIAGNOSIS OF BRUCELLOSIS | 2022 |
|
RU2785906C1 |
| METHOD FOR DIFFERENTIATING IN VITRO POSTVACCINAL AND INFECTIOUS BRUCELLOSIS ACCORDING TO DEGREE OF BODY HYPERSENSITIVITY TO BRUCELLA | 2015 |
|
RU2574207C1 |
| METHOD OF USING COMPLEX OF WATER-SOLUBLE ANTIGENS OF PLAGUE MICROBE FOR EVALUATION OF ANTIPLAGUE IMMUNITY LEVEL | 2019 |
|
RU2725872C1 |
| METHOD FOR ASSESSING POSTVACCINAL IMMUNITY AGAINST BRUCELLOSIS | 2019 |
|
RU2740009C1 |
| METHOD FOR ASSESSING IMMUNOGENICITY OF LIVE PLAGUE VACCINE USING IN VITRO ANTIGEN SPECIFIC CELLULAR TESTS | 2018 |
|
RU2680697C1 |
| METHOD FOR PREVENTING INFLUENZA BY COMBINED APPLICATION OF INTERFERON GAMMA AND INACTIVATED ANTI-INFLUENZA VACCINE | 2011 |
|
RU2546540C2 |
| METHOD OF EVALUATING IMMUNOGENECITY OF ANTI-BRICELLOSIS VACCINE STRAINS | 2009 |
|
RU2419096C2 |
| METHOD OF EVALUATION OF REACTIVITY AND IMMUNOLOGICAL SAFETY OF VACCINE | 1995 |
|
RU2086983C1 |
